Format

Send to

Choose Destination
Cell Rep. 2013 Oct 31;5(2):323-30. doi: 10.1016/j.celrep.2013.09.004. Epub 2013 Oct 10.

Bisphosphonates target B cells to enhance humoral immune responses.

Author information

1
Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, 20132 Milan, Italy; Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115, USA.

Abstract

Bisphosphonates are a class of drugs that are widely used to inhibit loss of bone mass in patients. We show here that the administration of clinically relevant doses of bisphosphonates in mice increases antibody responses to live and inactive viruses, proteins, haptens, and existing commercial vaccine formulations. Bisphosphonates exert this adjuvant-like activity in the absence of CD4(+) and γδ T cells, neutrophils, or dendritic cells, and their effect does not rely on local macrophage depletion, Toll-like receptor signaling, or the inflammasome. Rather, bisphosphonates target directly B cells and enhance B cell expansion and antibody production upon antigen encounter. These data establish bisphosphonates as an additional class of adjuvants that boost humoral immune responses.

PMID:
24120862
PMCID:
PMC3838640
DOI:
10.1016/j.celrep.2013.09.004
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center